Persistent Fetal SVT in a COVID-19 Positive Pregnancy
Menorah Medical Center
sars-cov-2, coronavirus infections, COVID-19, upraventricular tachycardia
Cardiovascular Diseases | Female Urogenital Diseases and Pregnancy Complications | Obstetrics and Gynecology | Virus Diseases
Background: Rapid introduction and spread of SARS-CoV-2 have posed unique challenges in understanding the disease, role in vertical transmission, and in developing management. We present a case of a patient with COVID-19 infection and fetus with new-onset fetal SVT.
Case: A 26-year-old gravida 4 para 2012 with third trimester COVID-19 infection was diagnosed with new onset fetal SVT. Successful cardioversion was achieved with flecainide. The patient was followed outpatient until induction of labor at 39 and 3/7 weeks of gestational age resulting in an uncomplicated vaginal delivery. Postpartum course was uncomplicated.
Conclusion: Fetal SVT is a potential complication of maternal COVID-19 infection. The use of transplacental therapy with flecainide is an appropriate alternative to digoxin in these cases.
Publisher or Conference
Case Reports in Obstetrics and Gynecology
Wang G, Stapley E, Peterson S, Parrott J, Clark-Ganheart C. Persistent Fetal SVT in a COVID-19 Positive Pregnancy. Case Rep Obstet Gynecol. 2022;2022:9933520. Published 2022 Jan 7. doi:10.1155/2022/9933520